The trial assessed the safety and pharmacokinetics of NN7128 in 30 healthy subjects. In the trial a significant prolongation of the half-life of NN7128 was observed. Furthermore, single doses of NN7128 were well tolerated with no serious adverse events.
George Vergis, Neose president and CEO, said: “We are encouraged by the safety and pharmacokinetic profile that NN7128 has demonstrated in this Phase I study. We look forward to continued progress in the clinical development of this compound.”